Full Professor of Radiology, Radiation Oncology and Nuclear Medicine at Université de Montréal, Associate Professor of Oncology at McGill University, Clinician Scientist at the CRCHUM, Dr. David Roberge trained in Radiation Oncology at McGill University and has subspecialty training at Stanford University and St-Jude Children’s Research Hospital.
Dr. Roberge was elected future president of the Canadian Association of Radiation Oncology (CARO) in 2022. He co-chairs the Central Nervous System Tumour Committee of the Canadian Cancer Trials Group (CCTG). In the clinic, in addition to co-directing a multidisciplinary cutaneous lymphoma clinic at McGill, Dr. Roberge has a keen interest in the technological advances in his specialty – patient imaging and precision radiotherapy treatment delivery. He was the first to develop stereotactic radiotherapy in Quebec, treating the first patient in 2007. A large team has since been built around CHUM’s CyberKnife, treating hundreds of patients each year. With more than 20 years of experience, Dr. Roberge has authored more than 140 articles, book chapters, and editorials. He is a visiting professor in many parts of the world, from the Middle East to South America. He is also the principal investigator of a large international trial in cranial radiosurgery.